PolyNovo Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Swami Raote

Algemeen directeur

AU$1.5m

Totale compensatie

Percentage CEO-salaris	46.4%
Dienstverband CEO	2.3yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.2yrs
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jan 08

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

Sep 22

When Should You Buy PolyNovo Limited (ASX:PNV)?

Jun 26

Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

May 30

Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Apr 18

Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Mar 23

Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Feb 05

Returns At PolyNovo (ASX:PNV) Are On The Way Up

Nov 16

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Nov 01

What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Jul 29

PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Jun 15

Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)

May 16

We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt

Apr 28

There's Been No Shortage Of Growth Recently For PolyNovo's (ASX:PNV) Returns On Capital

Mar 07

Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?

Dec 13

PolyNovo Limited's (ASX:PNV) CEO Compensation Looks Acceptable To Us And Here's Why

Oct 19

Is PolyNovo (ASX:PNV) Using Debt In A Risky Way?

May 08

News Flash: 7 Analysts Think PolyNovo Limited (ASX:PNV) Earnings Are Under Threat

Feb 27

Earnings Update: PolyNovo Limited (ASX:PNV) Just Reported And Analysts Are Trimming Their Forecasts

Feb 25

Is PolyNovo Limited (ASX:PNV) Potentially Undervalued?

Feb 17

Analyse CEO-vergoeding

Hoe is Swami Raote's beloning veranderd ten opzichte van PolyNovo's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$2m	AU$707k	AU$5m
Mar 31 2024	n/a	n/a	AU$3m
Dec 31 2023	n/a	n/a	AU$2m
Sep 30 2023	n/a	n/a	-AU$2m
Jun 30 2023	AU$2m	AU$617k	-AU$5m

Compensatie versus markt: De totale vergoeding ($USD 990.35K ) Swami } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 1.10M ).

Compensatie versus inkomsten: De vergoeding van Swami is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Swami Raote

2.3yrs

Tenure

AU$1,523,944

Compensatie

Mr. Swami Raote, B. Pharmacy, M.B.A, serves as Director at PolyNovo Limited since September 2022. He serves Entrepreneurs in Residence at DigitalDx Ventures. He serves as Chief Executive Officer at PolyNov...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Swami Raote	CEO & Director	2.3yrs	AU$1.52m	geen gegevens
Jan-Marcel Gielen	Chief Financial Officer	5.9yrs	AU$371.95k	0.093% A$ 1.3m
David McQuillan	Chief Technical & Scientific Officer	2.2yrs	AU$538.84k	0.097% A$ 1.3m
Philip Scorgie	Chief Information Officer	1.5yrs	AU$329.02k	geen gegevens
Lior Harel	General Counsel & Company Secretary	less than a year	geen gegevens	geen gegevens
Ingrid Anderson	Chief People Officer	less than a year	geen gegevens	geen gegevens
Edward Graubart	President of North America	5.2yrs	geen gegevens	geen gegevens
Ahmed Hassan	Chief Manufacturing & Supply Chain Officer	less than a year	geen gegevens	geen gegevens
Joseph Amaral	Chief Medical Officer	less than a year	geen gegevens	geen gegevens
David Morris	President of Asia Pacific	less than a year	geen gegevens	geen gegevens

1.2yrs

Gemiddelde duur

Ervaren management: Het managementteam van PNV wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.2 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Swami Raote	CEO & Director	2.2yrs	AU$1.52m	geen gegevens
Robyn Elliott	Independent Non-Executive Director	5.1yrs	AU$95.00k	0.011% A$ 148.1k
David Williams	Independent Non-Executive Chairman	10.8yrs	AU$139.43k	3.1% A$ 42.4m
Andrew Lumsden	Independent Non-Executive Director	3.4yrs	AU$95.00k	0.014% A$ 198.0k
Leon Hoare	Independent Non-Executive Director	8.8yrs	AU$95.02k	0.16% A$ 2.2m
Christine Emmanuel-Donnelly	Independent Non-Executive Director	4.5yrs	AU$95.00k	0.039% A$ 536.1k

4.8yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van PNV wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

PolyNovo Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Independent Non-Executive Director recently sold AU$261k worth of stock

PolyNovo Limited Announces Retirement of Bruce Rathie as Non-Executive Director

Non-Executive Independent Director recently sold AU$1.9m worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2024

Insufficient new directors

PolyNovo Limited, Annual General Meeting, Nov 03, 2023

Recent updates

Is It Time To Consider Buying PolyNovo Limited (ASX:PNV)?

Now 21% undervalued

Independent Non-Executive Director recently sold AU$261k worth of stock

PolyNovo Limited Announces Retirement of Bruce Rathie as Non-Executive Director

Non-Executive Independent Director recently sold AU$1.9m worth of stock

Now 21% undervalued

PolyNovo Limited, Annual General Meeting, Oct 28, 2024

PolyNovo (ASX:PNV) Is Experiencing Growth In Returns On Capital

Now 20% undervalued

Price target increased by 7.0% to AU$2.53

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

Now 24% undervalued

Price target increased by 8.8% to AU$2.37

Consensus EPS estimates increase by 15%

PolyNovo Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Insufficient new directors

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

Now 21% undervalued

Now 23% undervalued

Now 20% undervalued

Price target increased by 9.7% to AU$2.14

When Should You Buy PolyNovo Limited (ASX:PNV)?

First half 2024 earnings released: EPS: AU$0.004 (vs AU$0.006 loss in 1H 2023)

Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S

Price target increased by 7.4% to AU$1.95

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

PolyNovo Limited, Annual General Meeting, Nov 03, 2023

Price target decreased by 9.5% to AU$1.88

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

Price target decreased by 7.8% to AU$2.07

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 65%, revenue upgraded

Forecast breakeven date pushed back to 2025

When Should You Buy PolyNovo Limited (ASX:PNV)?

Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

Price target decreased by 11% to AU$2.25

Forecast breakeven date pushed back to 2025

Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Independent Non-Executive Chairman recently sold AU$9.7m worth of stock

Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Now 23% undervalued after recent price drop

Forecast breakeven date moved forward to 2023

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.002 profit in 1H 2022)

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

Price target increased by 13% to AU$2.36

Consensus EPS estimates upgraded to AU$0.0002 loss

Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Forecast breakeven date pushed back to 2024

Price target increased to AU$1.98

Price target increased to AU$1.90

Returns At PolyNovo (ASX:PNV) Are On The Way Up

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Independent Non-Executive Chairman recently bought AU$202k worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2022

PolyNovo Limited Announces Re-Designation of David McQuillan as Chief Technical and Scientific Officer

Price target increased to AU$1.68

Full year 2022 earnings: EPS misses analyst expectations

Now 21% undervalued

PolyNovo Limited Announces First Patient Enrolled in Clinical Trial of NovoSorb SynPath Treatment for Diabetic Foot Ulcers

PolyNovo Limited Announces CEO Changes

PolyNovo Limited Announces CEO Changes

What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Consensus forecasts updated

Now 21% undervalued

PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Independent Non-Executive Chairman recently bought AU$956k worth of stock

Now 23% undervalued